摘要
目的比较康柏西普(conbercept)与雷珠单抗(ranibizumab)治疗早产儿视网膜病变(ROP)的效果。方法以郑州大学附属儿童医院2017年6月至2019年6月收治的ROP 96例(192眼)为研究对象。按照随机数字表法将其分为A、B两组,每组48例(96眼)。A组与B组分别以雷珠单抗及康柏西普进行玻璃体内注射治疗。A组雷珠单抗需要每月进行注射,共注射6次;B组,康柏西普前3个月每月注射1次,后3个月仅注射1次,共4次。随访6个月,观察两组患儿治愈及复发情况。结果A组治愈率为72.92%(70/96),与B组的治愈率75.00%(72/96)相近(χ^(2)=0.054,P=0.816);两组复发率均为6.25%(6/96)。结论康柏西普治疗ROP的效果与雷珠单抗相当,但注药次数较少而且较进口的雷珠单抗更具有适用性。
Objective To compare the efficacy of conbercept and ranibizumab for the treatment of retinopathy of prematurity(ROP).Methods A total of 192 eyes of 96 cases of ROP from Jun.2017 to Jun.2019 in the Children’s Hospital of Zhengzhou University were included as the research object.All cases were divided into group A and group B,based on random number table methods,with 96 eyes of 48 cases in each group.Group A recevied intravitreal injection of ranibizumab once a month for 6 times.In group B,conbercept was injected once a month in the first 3 months and once a month in the next 3 months,a total of 4 times.The two groups of children were followed up for 6 months to observe the cure and recurrence.Results The cure rate of group A were 72.92%(70/96),which was similar to the 75.00%(72/96)of group B(χ^(2)=0.054,P=0.816).The recurrence rate of both groups was 6.25%(6/96).Conclusion Conbercept and ranibizumab have similar efficacy for the treatment of ROP,but the number of conbercept injections is less and it is more applicable than ranibizumab.
作者
王飞
孙爽
孙先桃
Wang Fei;Sun Shuang;Sun Xiantao(Department of Ophthalmology,Children’s Hospital Appiliated to Zhengzhou University,Henan Children’s Hospital,Zhengzhou Children’s Hospital,Zhengzhou 450000,China)
出处
《中华眼外伤职业眼病杂志》
2021年第10期791-796,共6页
Chinese Journal of Ocular Trauma and Occupational Eye Disease
